“Promotional graphic for Tisento Therapeutics. On the left, pink text reads ‘Let’s Connect at #Euromit2026!’. Below, white text states that the company is on a mission to deliver medicines that address what matters most, starting with the rare mitochondrial disease MELAS. On the right, the Tisento Therapeutics logo appears, featuring a stylized mitochondria-like symbol. The background shows a night sky with green and purple aurora borealis. At the bottom left, the website ‘www.tisentotx.com’ is written in green.

@tisentotx.bsky.social is proud to support #euromit2026 as a Silver Sponsor! Our clinical program in the rare #MitochondrialDisease #MELAS is evaluating zagociguat’s effect on symptoms that matter most to patients—including fatigue and cognitive dysfunction. Visit our booth at #Euromit2026#WeHearYou

Today is #RareDiseaseDay. We stand with the 300 million people globally who live with a rare disease, including those with rare #MitochondrialDiseases like #MELAS. Read stories of #RareDisease heroes: www.rarediseaseday.org/heroes/ #Biosky

There are 6,000+ rare diseases—and expertise and information are often scarce. In health systems designed for common diseases, rare diseases often face inequities. download2.rarediseaseday.org/2025/campaig... #RareDiseaseDay #HealthEquity #MitochondrialDisease #MELAS #Biosky

The #MELAS Externally Led Patient-Focused Drug Development meeting is today! Hosted by #MitoAction, the event invites those affected by MELAS to share their experiences and be part of shaping #MitochondrialDisease care and treatment. www.mitoaction.org/join-the-cau... #Biosky

Next week, #MitoAction is hosting an Externally Led Patient-Focused Drug Development meeting dedicated to #MELAS. We’re proud to sponsor this important opportunity to elevate MELAS voices. Virtual event open to all! Register: www.mitoaction.org/join-the-cau... #Biosky

We believe meaningful innovation starts with listening. That’s why we’re conducting an interview study with adolescents (12-17 years) who are living with #MELAS, a rare #MitochondrialDisease. The final group is enrolling now! www.tisentotx.com/s/Tisento-Ad... #biosky

MitoAction Mito Town Meeting | Friday, January 16 | Noon to 2:45pm ET Hear from Jennifer Chickering, our Vice President of Program Leadership, around 2pm!

What will 2026 bring for the #MitochondrialDisease community? Join the @MitoAction town meeting on Friday to hear insights from advocates, clinicians, and industry leaders, including our VP of Program Leadership, Jennifer Chickering. Register here: www.mitoaction.org/resources/20... #Biosky #MELAS

Tomorrow, Chad Glasser, VP of Clinical Research, will present at the Wellcome Mitochondrial Medicine Conference on assessing cognitive function in #PrimaryMitochondrialDisease clinical trials. #MELAS #ClinicalDevelopment #Biosky coursesandconferences.wellcomeconnectingscience.org/event/mitoch...

Findings from our #MELAS interview study were recently published in the Journal of Patient-Reported Outcomes. The study highlighted the symptoms & impacts most important to patients and informed our Phase 2b PRIZM study. #MitochondrialDisease #PRO #Biosky www.tisentotx.com/news/tisento...

Meet Morena! She’s a mom and a retired nurse, loves deeply connecting with people, and lives with #MELAS. We’re honored to support #MitoCon in telling stories of those affected by this #RareDisease. See Morena’s story (Italian w/ English subtitles): youtu.be/bFciPejLNPg #Biosky

Last call for our PRIZM clinical study in #MELAS! We’re expecting to complete enrollment in the next few weeks. Those who are interested in participating at one of our sites around the world can find out more by talking to their doctor. #ClinicalResearch #MitochondrialDisease www.tisentotx.com/prizm

#MELAS can affect multiple organ systems and frequently causes a range of severe and burdensome symptoms. We are working on what could be the first treatment for this devastating disease through our PRIZM MELAS study. #WorldMitoWeek2025 #MitochondrialDisease #DecodeTheMitoPuzzle #Biosky

Collaboration among researchers, clinicians & patients translates science into real-world impact for those with #MitochondrialDisease. We’re proud to be part of this network with our PRIZM #MELAS clinical study. #WorldMitoWeek2025 #DecodeTheMitoPuzzle #Biosky www.tisentotx.com/prizm

Next week is #WorldMitoWeek2025. We love the theme, #DecodeTheMitoPuzzle, focused on connecting science to lived experiences with #MitochondrialDisease. Our PRIZM #MELAS study is rooted in this approach & is screening now but not for much longer! #WeHearYou #Biosky www.tisentotx.com/prizm

📢 New publication in Cells explores how pseudohypoxia in MELAS suppresses MNRR1 through HIF2α—uncovering a promising druggable pathway for mitochondrial disease.

🧬 WSU EACPHS faculty co-authored this breakthrough work.
🔗 doi.org/10.3390/cell...

#Mitochondria #MELAS #RareDiseases #WayneState #MNRR1

Our #MELAS open-label extension study has officially started! The first participant is now enrolled after completing treatment in our global Phase 2b PRIZM study. PRIZM is actively enrolling and expected to complete screening in the next months. #Biosky www.tisentotx.com/news/first-p...

We’re proud to advance patient-focused therapeutic development for #MitochondrialDiseases at two important events. #ReaganUdallFoundationForFDA #MitoAction #ClinicalDevelopment #MELAS www.tisentotx.com/news/tisento...

<em>Headache: The Journal of Head and Face Pain</em> | AHS Journal | Wiley Online Library Calcitonin gene-related peptide (CGRP) is a potent cerebral vasodilator and part of the trigeminal migraine cascade. Newer migraine therapies target CGRP signaling for both acute and preventative man...

Open Access:
A Kuczynski & W Kingston share 1st cases of #galcanezumab use in someone w #MELAS & #eptinezumab in an individual w #CADASIL, suggesting #CGRP driven processes driving #migraine even in those w genetically determined disease
headachejournal.onlinelibrary.wiley.com/doi/full/10....

In today’s Pediatric Neurology CPC #GrandRounds, the case of the mitochondrial disorder #MELAS was discussed in a 8 month old presenting with encephalopathy.

blog update: #Melas #Tauschticket-Bettellei www.mela.de/archives/1084-Melas-Taus...